Pharmaceutical

NICE approves GSK’s belantamab mafodotin for blood cancer

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Jun 17, 2025 - 06:00
NICE approves GSK’s belantamab mafodotin for blood cancer
NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.
Read the original article

Tags:

Previous Article

EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gilead and Tentarix partner on cancer and inflammation therapies

Gilead and Tentarix partner on cancer and inflammation ...

Aug 16, 2023

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

Casgevy: Launch sequence and price analysis of the firs...

Aug 3, 2024

Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters

Listen: Sarepta’s pivotal moment, biotech’s big week, &...

Apr 21, 2023